Na+/H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium-glucose co-transporter 1-mediated glucose absorption in the small intestine

被引:13
|
作者
Chan, Leo K. Y. [1 ]
Wang, Yi [1 ]
Ng, Enders K. W. [2 ]
Leung, Po Sing [1 ]
机构
[1] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Room 609A, Shatin, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Surg, Prince Wales Hosp, Fac Med, Shatin, Hong Kong, Peoples R China
来源
DIABETES OBESITY & METABOLISM | 2018年 / 20卷 / 03期
关键词
diabetes; glucose intolerance; NHE3; inhibitor; postprandial hyperglycaemia; HYPOGLYCEMIC AGENT; TRANSPORTER SGLT1; RECEPTOR; ENTEROCYTES; ACTIVATION; KINASE; GROWTH; NHE3;
D O I
10.1111/dom.13151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimTo elucidate the role of Na+/H+ exchanger 3 (NHE3) in sodium-glucose co-transporter 1 (SGLT1)-mediated small intestinal brush border membrane (BBM) glucose absorption and its functional implications in type 2 diabetes mellitus (T2DM). Materials and MethodsHuman jejunal samples were obtained from patients undergoing gastrectomy. C-14-glucose absorption was measured by liquid scintillation counting. NHE3 expression was suppressed by siRNA-mediated knockdown or augmented in Caco2 cells. Glucose and insulin tolerance in db/db and m+/db mice was assessed with oral and intraperitoneal glucose tolerance tests, and an intraperitoneal insulin tolerance test. Insulin resistance and -cell function were assessed using homeostatic model assessment of insulin resistance and -cell function. ResultsNHE3 expression was upregulated in db/db mouse jejunal BBM and high-glucose-treated Caco2 cells. NHE3 blockade impaired SGLT1-mediated glucose absorption in human jejunum, m+/db and db/db mouse jejunums, and Caco2 cells, via serum/glucocorticoid-regulated kinase 1 (SGK1). NHE3 knockdown suppressed SGLT1-mediated glucose uptake and reduced mRNA and protein levels of SGK1 and SGLT1, which were conversely enhanced by NHE3 overexpression. Chronic S3226 treatment diminished postprandial glucose levels and ameliorated glucose intolerance in db/db mice. ConclusionNHE3 is essential in the modulation of small intestinal BBM glucose absorption. Our findings provide a rationale for future possible clinical application of NHE3 for treatment of T2DM through reducing intestinal glucose uptake and counteracting postprandial hyperglycaemia.
引用
收藏
页码:709 / 717
页数:9
相关论文
共 50 条
  • [21] Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
    Rosenthal, Norm
    Meininger, Gary
    Ways, Kirk
    Polidori, David
    Desai, Mehul
    Qiu, Rong
    Alba, Maria
    Vercruysse, Frank
    Balis, Dainius
    Shaw, Wayne
    Edwards, Robert
    Bull, Scott
    Di Prospero, Nicholas
    Sha, Sue
    Rothenberg, Paul
    Canovatchel, William
    Demarest, Keith
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 28 - 43
  • [22] Inhibition of gastric emptying by intestinal hexoses is dependent on absorption via sodium-glucose co-transporter (SGLT1).
    Raybould, HE
    Tabrizi, Y
    Meyer, JH
    FASEB JOURNAL, 1997, 11 (03): : 189 - 189
  • [23] Prospect of Sodium-Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
    Yang, Yinqiu
    Zhao, Chenhe
    Ye, Yangli
    Yu, Mingxiang
    Qu, Xinhua
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [24] Sodium-Glucose Co-Transporter 2 Inhibitors and the Risk of Fractures among Patients with Type 2 Diabetes
    Abrahami, Devin
    Douros, Antonios
    Yin, Hui
    Yu, Oriana H. Y.
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 23 - 23
  • [25] Use of sodium-glucose co-transporter 2 inhibitors among US patients with type 2 diabetes
    Rajpathak, S.
    Yu, S.
    Engel, S. S.
    Li, Z.
    Fan, C. -P. S.
    Tang, J.
    Hanna, B.
    Williams, J.
    McNeill, A.
    DIABETOLOGIA, 2015, 58 : S180 - S180
  • [26] Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Torimoto, Keiichi
    Okada, Yosuke
    Koikawa, Kenji
    Tanaka, Yoshiya
    DIABETOLOGY & METABOLIC SYNDROME, 2017, 9
  • [27] Early effects of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes: study based on continuous glucose monitoring
    Keiichi Torimoto
    Yosuke Okada
    Kenji Koikawa
    Yoshiya Tanaka
    Diabetology & Metabolic Syndrome, 9
  • [28] Pharmacodynamics, Efficacy and Safety of Sodium-Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
    Scheen, Andre J.
    DRUGS, 2015, 75 (01) : 33 - 59
  • [29] Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes
    Solini, Anna
    Rossi, Chiara
    Mazzanti, Chiara M.
    Proietti, Agnese
    Koepsell, Hermann
    Ferrannini, Ele
    DIABETES OBESITY & METABOLISM, 2017, 19 (09): : 1289 - 1294
  • [30] A CASE SERIES OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR USE IN TYPE 1 DIABETES IN A RURAL SETTING
    Drake, Stephanie
    May, Stephen
    NEPHROLOGY, 2024, 29 : 71 - 72